Why the Centrica share price rose 6% in September

G A Chester looks at Centrica’s September price rise and whether the British Gas owner has finally turned the corner.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

British Gas owner Centrica (LSE: CNA) has been the most unloved stock on the FTSE 100 over the last five years. Its shares have fallen more than 75%. But holders enjoyed some respite in September. After seven consecutive months of declines, the shares climbed from 69.7p to 73.7p — a rise of 6% compared with the Footsie’s gain of 3%.

The question now is whether Centrica’s finally turned the corner, or whether September’s performance is a mere interlude in an entrenched downward trend. Let’s have a look at why the shares advanced 6% over the month.

Broker news

Centrica released just two inconsequential notices on the regulatory newswire in September, so we have to look elsewhere for drivers of the movement in the share price.

There was a fair bit of broker news on the stock. JP Morgan Cazenove reiterated its ‘neutral’ rating in the first week of the month, but cut its price target from 110p to 75p. Similarly, in the second week, Berenberg reiterated its ‘hold’ rating, but cut its target from 140p to 80p. The market brushed off the target downgrades, perhaps focusing more on Berenberg’s view that the stock is inexpensive and the firm could be a candidate for a takeover bid.

Moving further into the month, there was unequivocally positive broker news. Describing Centrica as a “value wildcard,” Jefferies upgraded its rating from ‘hold’ to ‘buy’ and put a 90p price target on the stock.

On the company’s strategy for stabilising the business, the broker said: “Clearly, there are execution risks relating to cost-cutting measures and disposals, but with the stock trading at a 50% discount to the utility sector (at historical lows of 8x forward price-to-earnings) and offering 6.7% cash yield, we see the risk-reward as attractive.”

Talks and shorts

On the subject of Centrica’s planned disposals, its shares were buoyed mid-month by a Sky News report. This claimed a consortium of infrastructure investors is in advanced talks to buy a 20% stake in the UK’s nuclear power stations for £1.2bn from Centrica and EDF Energy.

Meanwhile, short positions in the stock held by investment giant BlackRock and hedge fund Marshall Wace were at a peak of 2.21% (worth £90m) in early September. This reduced to 2.07%, with Marshall Wace modestly lowering its position (i.e. buying shares) over the course of the month.

The buying by the short-seller may have added a little further support for Centrica’s share price on top of that provided by the broadly positive broker commentaries and Sky News report.

Value wildcard

So far in October, Centrica has given up its 6% September gain and more, down 8% at the time I’m writing. There’s been no material news I can see for the dip, so it looks like fickle short-term sentiment is driving things at the moment.

However, I think Centrica is fundamentally cheap, if it can successfully execute on its cost-cutting and disposals strategy. As such, and given the size of the discount to its utility peers, I agree with Jefferies’ characterisation of it as a “value wildcard.

Personally, though, I see some better value opportunities in the market. However, if I already owned Centrica shares, I’d be inclined to continue to hold them, and await concrete news on cost-cutting and disposals.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »